HRAS and cancer: However, the ability of KRAS to be alternatively prenylated in response to farnesyl transferase inhibitor treatment rendered this approach ineffective for KRAS-mutant cancers (13), although these inhibitors have shown some efficacy in HRAS-mutant malignancies (14).